Abbott settles another part of US Tricor antitrust litigation
This article was originally published in Scrip
Executive Summary
Abbott Laboratories has agreed to pay 23 states and the District of Columbia $22.5 million to settle claims that the company blocked generic drug makers from coming onto the US market with their versions of the branded hypolipaemic Tricor (micronised fenofibrate) through anticompetitive actions involving alleged minor changes in formulation and meritless patent infringement suits.